Resources
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 24 June 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 12th meeting on 24 June 2022
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
Evaluation of the Chronic Pain MedsCheck Trial – Final report
This report presents the results of the project to trial a pharmacist-led support service for patients who take medication to manage chronic pain.
National Site of Recognition Steering Committee communique – 20 January 2022
This communique outlines the main points from discussion from the National Site of Recognition Steering Committee meeting including the next steps in the development of the National Site of Recognition for thalidomide survivors and their families.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 18th February 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 11th meeting on 18th February 2022.
National Site of Recognition Steering Committee communique – 9 December 2021
Details of the second meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 9 December 2021.
National Site of Recognition Steering Committee communique – 1 November 2021
Details of the meeting of the National Site of Recognition for thalidomide survivors and their families Steering Committee held on 1 November 2021.
Australian National Diabetes Strategy 2021–2030
The Australian Government has developed a new national diabetes strategy. This strategy updates and prioritises the response to diabetes for all governments.
COVID-19 vaccination – vaccination data – 31 October 2021
This data file contains statistical data about Australia's COVID-19 vaccinations.
National Health Reform Agreement (NHRA) – Long-term health reforms roadmap
This reform roadmap outlines how the Australian Government and state and territory governments will work together to improve health outcomes for all Australians and ensure our health system is sustainable.
National Strategic Action Plan for Heart Disease and Stroke
The National Strategic Action Plan for Heart Disease and Stroke provides a roadmap to achieve a healthier Australia by tackling heart disease and stroke, two of the nation’s biggest killers.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 8th October 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 10th meeting on 8th October 2021.
Cerliponase alfa terms of reference and protocol questions
This report outlines the Cerliponase alfa 24 month review terms of reference and protocol questions
Migalastat terms of reference and protocol questions
This report outlines the Migalastat 24 month review terms of reference and protocol questions.
Australian Government response to National Rural Health Commissioner’s report on improving the access, quality and distribution of allied health services in rural and remote Australia
This is the Australian Government response to the former Commissioner, Emeritus Professor Paul Worley’s report. The response outlines the work that will be undertaken to improve the capacity, quality, and distribution of allied health services to meet the needs of rural and remote Australians.
Rare Diseases – Support, Education and Training Grant Opportunity GO2815
Rare Diseases – Support, Education and Training Grant Opportunity general feedback for the information of grant applicants.
Heart Disease and Stroke – Early Detection
This document provides general feedback on the Grant Opportunity for Heart Disease and Stroke – Early Detection GO2796 for the information of grant applicants.
Heart Disease and Stroke – Support for Recovery
This document provides general feedback on the Grant Opportunity for Heart Disease and Stroke – Support for Recovery GO2797 for the information of grant applicants.
Macular disease – Population groups at risk general feedback for applicants
This document provides general feedback on the grant opportunity for Macular Disease – Consumer awareness and education – Population groups at risk for the information of grant applicants.
National Cancer Screening Register – addendum to privacy impact assessment
This report summarises developments in the national bowel and cervical screening programs and the National Cancer Screening Register since the initial privacy impact assessment was done.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 17th June 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 9th meeting on 17 June 2021.
The National Strategic Action Plan for Pain Management
The action plan aim to improve the quality of life for people living with chronic pain in Australia.
Advisory Committee for the COVID-19 Response for People with Disability – Meeting key outcomes 12 May 2021
This communique is for the meetings of the Advisory Committee on Health Emergency Response to Coronavirus (COVID-19) for People with Disability on 12 May 2021.
EAF support categories fact sheet
This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Extraordinary Assistance Fund (EAF).
Thalidomide health practitioner evidence form
This form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).
Date last updated: